{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T22:10:22Z","timestamp":1736806222253,"version":"3.33.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-024-01140-5","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:47:47Z","timestamp":1736761667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic Ductal Adenocarcinoma with Medullary Features and a Complete Pathological Response After Neoadjuvant FOLFIRINOX: A Case Report and Literature Review"],"prefix":"10.1007","volume":"56","author":[{"given":"Rodrigo Gomes","family":"Taboada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Fernanda","family":"Arruda Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina Miranda","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirce Maria","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warley Abreu","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro Landskron","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago Cordeiro","family":"Felismino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Hugo Fonseca","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"publisher","first-page":"175883592412652","DOI":"10.1177\/17588359241265213","volume":"16","author":"VHF de Jesus","year":"2024","unstructured":"de Jesus VHF, Donadio MDS, de Brito \u00c2BC, Gentilli AC. A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas? Ther Adv Med Oncol. 2024;16:17588359241265212.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1140_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1140_CR3","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1140_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2019.12.013","volume":"52","author":"F van Maldegem","year":"2020","unstructured":"van Maldegem F, Downward J. Mutant KRAS at the heart of tumor immune evasion. Immunity. 2020;52(1):14\u20136.","journal-title":"Immunity"},{"issue":"20","key":"1140_CR5","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.3390\/cancers15205015","volume":"15","author":"VHF de Jesus","year":"2023","unstructured":"de Jesus VHF, Mathias-Machado MC, de Farias JPF, Aruquipa MPS, J\u00e1come AA, Peixoto RD. Targeting KRAS in pancreatic ductal adenocarcinoma: the long road to cure. Cancers (Basel). 2023;15(20):5015.","journal-title":"Cancers (Basel)."},{"issue":"24","key":"1140_CR6","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman NA, Burchard PR, Dunne RF, Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022;40(24):2789\u2013805.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1140_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","volume":"70","author":"C Luchini","year":"2021","unstructured":"Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70(1):148\u201356.","journal-title":"Gut"},{"issue":"11","key":"1140_CR8","doi-asserted-by":"publisher","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","volume":"6","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Berton D, Curigliano G, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw Open. 2023;6(11):e2341165.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1140_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol"},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"e2200706","DOI":"10.1200\/PO.22.00706","volume":"7","author":"T Coston","year":"2023","unstructured":"Coston T, Desai A, Babiker H, et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: mayo clinic experience. JCO Precis Oncol. 2023;7:e2200706.","journal-title":"JCO Precis Oncol"},{"key":"1140_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","volume":"188","author":"J Ta\u00efeb","year":"2023","unstructured":"Ta\u00efeb J, Sayah L, Heinrich K, et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Eur J Cancer. 2023;188:90\u20137.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1140_CR12","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1245\/s10434-011-2211-4","volume":"19","author":"CW Tzeng","year":"2012","unstructured":"Tzeng CW, Fleming JB, Lee JE, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19(6):2045\u201353.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1140_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7453\/gahmj.2013.008","volume":"2","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med. 2013;2(5):38\u201343.","journal-title":"Glob Adv Health Med"},{"key":"1140_CR14","first-page":"80","volume":"2","author":"AR-D Val","year":"2015","unstructured":"Val AR-D, Medina-Franco H, Chan C. Medullary carcinoma of the pancreas: case reports and literature review. J Cancerol. 2015;2:80\u20133.","journal-title":"J Cancerol"},{"key":"1140_CR15","doi-asserted-by":"publisher","first-page":"1082927","DOI":"10.3389\/fonc.2022.1082927","volume":"12","author":"J von den Driesch","year":"2022","unstructured":"von den Driesch J, Fl\u00f6ttmann J, Prall F, Mullins CS, Linnebacher M, B\u00fcrtin F. HROP68: A rare case of medullary pancreatic cancer-characterization and chemosensitivity of the first patient-derived cell line. Front Oncol. 2022;12:1082927.","journal-title":"Front Oncol"},{"issue":"1","key":"1140_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40792-018-0487-3","volume":"4","author":"A Yago","year":"2018","unstructured":"Yago A, Furuya M, Mori R, et al. Medullary carcinoma of the pancreas radiologically followed up as a cystic lesion for 9 years: a case report and review of the literature. Surg Case Rep. 2018;4(1):80.","journal-title":"Surg Case Rep"},{"key":"1140_CR17","first-page":"38","volume":"2022","author":"MK Saad","year":"2022","unstructured":"Saad MK, Triantafyllou E, Papaleo D, Cahn V, Saikaly E, Proske YM. Medullary carcinoma of the pancreas: report of a rare pancreatic malignancy and review of literature. UEG Week. 2022;2022:38.","journal-title":"UEG Week"},{"key":"1140_CR18","unstructured":"Hruban R, Adsay N, Esposito I, et al. Pancretic ductal adenocarcinoma. In: WHO Classification of Tumours Editorial Board, ed. World Health Organization (WHO) Classification of Digestive System Tumours. Fifth edition ed. 2019:322\u201332."},{"issue":"11","key":"1140_CR19","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.humpath.2006.06.024","volume":"37","author":"N Banville","year":"2006","unstructured":"Banville N, Geraghty R, Fox E, et al. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol. 2006;37(11):1498\u2013502.","journal-title":"Hum Pathol"},{"issue":"6","key":"1140_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","volume":"12","author":"B Rousseau","year":"2022","unstructured":"Rousseau B, Bieche I, Pasmant E, et al. PD-1 Blockade in solid tumors with defects in polymerase epsilon. Cancer Discov. 2022;12(6):1435\u201348.","journal-title":"Cancer Discov"},{"issue":"7","key":"1140_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/MPA.0000000000001588","volume":"49","author":"V Kryklyva","year":"2020","unstructured":"Kryklyva V, Ter Linden E, Kroeze LI, et al. Medullary pancreatic carcinoma due to somatic POLE mutation: a distinctive pancreatic carcinoma with marked long-term survival. Pancreas. 2020;49(7):999.","journal-title":"Pancreas"},{"key":"1140_CR22","doi-asserted-by":"crossref","unstructured":"Mathias-Machado MC, Oliveira LJ, Fonseca de Jesus VH, Peixoto RD, Alpino. Molecular features and targeted therapy in KRAS wild-type pancreatic cancer. Med Res Arch 2023;11(4):1\u201330.","DOI":"10.18103\/mra.v11i4.3764"},{"issue":"12","key":"1140_CR23","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","volume":"28","author":"PA Philip","year":"2022","unstructured":"Philip PA, Azar I, Xiu J, et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 2022;28(12):2704\u201314.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1140_CR24","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219\u201326.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1140_CR25","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1200\/JCO.18.01798","volume":"37","author":"F Innocenti","year":"2019","unstructured":"Innocenti F, Ou FS, Qu X, et al. Mutational analysis of patients with colorectal cancer in CALGB\/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol. 2019;37(14):1217\u201327.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1140_CR26","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392\u2013400.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1140_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929\u201338.","journal-title":"Ann Oncol"},{"issue":"10","key":"1140_CR28","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","volume":"55","author":"PMK Westcott","year":"2023","unstructured":"Westcott PMK, Muyas F, Hauck H, et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nat Genet. 2023;55(10):1686\u201395.","journal-title":"Nat Genet"},{"issue":"20","key":"1140_CR29","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.3390\/cancers15205090","volume":"15","author":"R Heregger","year":"2023","unstructured":"Heregger R, Huemer F, Steiner M, Gonzalez-Martinez A, Greil R, Weiss L. Unraveling resistance to immunotherapy in MSI-high colorectal cancer. Cancers (Basel). 2023;15(20):5090.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1140_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00428-021-03205-3","volume":"480","author":"C Luchini","year":"2022","unstructured":"Luchini C, Mafficini A, Chatterjee D, et al. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. Virchows Arch. 2022;480(6):1261\u20138.","journal-title":"Virchows Arch"},{"key":"1140_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.humpath.2022.06.009","volume":"132","author":"C Luchini","year":"2023","unstructured":"Luchini C, Scarpa A. Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology, and clinical implications. Hum Pathol. 2023;132:176\u201382.","journal-title":"Hum Pathol"},{"key":"1140_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.humpath.2022.12.016","volume":"135","author":"H Matsubayashi","year":"2023","unstructured":"Matsubayashi H, Oishi T, Sasaki K, et al. Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type. Hum Pathol. 2023;135:54\u201364.","journal-title":"Hum Pathol"},{"key":"1140_CR33","doi-asserted-by":"crossref","unstructured":"Garcia Garcia de Paredes A, Graham RP, Levy MJ, et al. Utility of mismatch repair protein expression screening via an endoscopic ultrasound assessment of treatment-naive pancreas ductal adenocarcinoma. Gut 2022;71(1):219\u201321.","DOI":"10.1136\/gutjnl-2021-324460"},{"issue":"suppl 4","key":"1140_CR34","doi-asserted-by":"publisher","first-page":"abstr 754","DOI":"10.1200\/JCO.2023.41.4_suppl.754","volume":"4","author":"M Mehdi","year":"2023","unstructured":"Mehdi M, Thapa B, Szabo A, et al. ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma. J Clin Oncol. 2023;4(suppl 4):abstr 754.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01140-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T21:42:49Z","timestamp":1736804569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01140-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01140-5","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"7 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"42"}}